SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
AssigneeSylentis S.A.U.
InventorsAna Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
Life of this patent
Estimating the term…
Abstract
The invention relates to methods and compositions for the treatment and/or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV).
Claims14
A method of treating dry eye and/or ocular pain in a subject in need thereof, said method comprising administering topically to the eye of the subject an siRNA having the sequence as set forth in SEQ ID NO:
- 2 and targeted to SEQ ID NO:
- 1, said siRNA administered at a dosage of 0.3 mg to 0.9 mg per day;
- wherein the dosage is effective in reducing dry eye and/or ocular pain in the subject undergoing treatment.
A unit dosage form for treating eye and/or ocular pain in a subject in need thereof, said dosage form comprising an siRNA having the sequence as set forth in SEQ ID NO:
- 2 and targeted to SEQ ID NO:
- 1 in a therapeutic amount of 0.3 mg to 0.9 mg, and a pharmaceutically acceptable carrier or diluent.
A kit for administering an siRNA having the sequence as set forth in SEQ ID NO:
- 2 and targeted to SEQ ID NO:
- 1, said kit comprising a dosage of the siRNA of 0.3 mg to 0.9 mg for daily administration, and printed instructions for administering the siRNA.
Dependencies are inferred from the claim text.